Finoriq research workspace
Zentalis Pharmaceuticals, Inc. (ZNTL) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Zentalis Pharmaceuticals, Inc. (ZNTL).
Company Snapshot
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
- Company
- Zentalis Pharmaceuticals, Inc. (ZNTL)
- Ticker
- ZNTL
- Market Cap
- $356.6M
- Latest Price
- $5.01
- Industry
- Biotech & Pharma
Zentalis Pharmaceuticals, Inc. (ZNTL) Recent Insider Transactions
Recent market insider transaction records indexed for Zentalis Pharmaceuticals, Inc. (ZNTL).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| Vultaggio VincentPAO and PFO | S | Disposed | -$16,699 | 2026-02-10 |
| Vultaggio VincentPAO and PFO | S | Disposed | -$8,086 | 2026-02-09 |
| Bruns IngmarChief Medical Officer | S | Disposed | -$802 | 2026-02-09 |
| EASTLAND JULIA MARIECEO & President | S | Disposed | -$2,127 | 2026-02-09 |
| Vultaggio VincentPAO and PFO | S | Disposed | -$72,772 | 2026-02-06 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.